189 related articles for article (PubMed ID: 28169145)
1. Poor Prognosis of Lower Inner Quadrant in Lymph Node-negative Breast Cancer Patients Who Received No Chemotherapy: A Study Based on Nationwide Korean Breast Cancer Registry Database.
Hwang KT; Kim J; Kim EK; Jung SH; Sohn G; Kim SI; Jeong J; Lee HJ; Park JH; Oh S;
Clin Breast Cancer; 2017 Jul; 17(4):e169-e184. PubMed ID: 28169145
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implication of the tumor location according to molecular subtypes in axillary lymph node-positive invasive ductal cancer in a Korean population.
Lim ST; Choi JE; Kim SJ; Kim HA; Kim JY; Park HK; Suh YJ
Breast Cancer Res Treat; 2016 Apr; 156(3):473-483. PubMed ID: 27041335
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implication of the primary tumor location in early-stage breast cancer: focus on lower inner zone.
Yang J; Tang S; Zhou Y; Qiu J; Zhang J; Zhu S; Lv Q
Breast Cancer; 2018 Jan; 25(1):100-107. PubMed ID: 28822078
[TBL] [Abstract][Full Text] [Related]
4. Diminished survival in patients with inner versus outer quadrant breast cancers.
Gaffney DK; Tsodikov A; Wiggins CL
J Clin Oncol; 2003 Feb; 21(3):467-72. PubMed ID: 12560437
[TBL] [Abstract][Full Text] [Related]
5. Tumor location is a prognostic factor for survival of Chinese women with T1-2N0M0 breast cancer.
Wu S; Zhou J; Ren Y; Sun J; Li F; Lin Q; Lin H; He Z
Int J Surg; 2014; 12(5):394-8. PubMed ID: 24657350
[TBL] [Abstract][Full Text] [Related]
6. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
[TBL] [Abstract][Full Text] [Related]
7. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer.
Chagpar AB; Hatzis C; Pusztai L; DiGiovanna MP; Moran M; Mougalian S; Sanft T; Evans S; Hofstatter E; Wilson LD; Lannin DR
Ann Surg Oncol; 2017 Oct; 24(10):3073-3081. PubMed ID: 28766195
[TBL] [Abstract][Full Text] [Related]
8. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
9. [Effect of the primary tumor location on the prognosis of breast invasive ductal carcinoma patients treated with radical mastectomy].
Wang YT; Chen ZJ; Zhang D; Zhou H; Cao XC; Wang X
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):686-692. PubMed ID: 31550859
[No Abstract] [Full Text] [Related]
10. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
11. Predictive of 21-gene recurrence score assay in non-estrogen receptor-positive and lymph node-negative breast cancer.
Lu K; Li H; Wu Z; Liu D; Ye H; Xu L; Liu Y
J BUON; 2018; 23(5):1297-1301. PubMed ID: 30570850
[TBL] [Abstract][Full Text] [Related]
12. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma.
Wong SM; Freedman RA; Sagara Y; Stamell EF; Desantis SD; Barry WT; Golshan M
Cancer; 2015 Dec; 121(24):4333-40. PubMed ID: 26376021
[TBL] [Abstract][Full Text] [Related]
13. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
14. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W;
J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570
[TBL] [Abstract][Full Text] [Related]
15. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
Falck AK; Fernö M; Bendahl PO; Rydén L
World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
[TBL] [Abstract][Full Text] [Related]
16. ER
Arciero CA; Guo Y; Jiang R; Behera M; O'Regan R; Peng L; Li X
Clin Breast Cancer; 2019 Aug; 19(4):236-245. PubMed ID: 30846407
[TBL] [Abstract][Full Text] [Related]
17. Intra-mammary tumor location does not influence prognosis but influences the prevalence of axillary lymph-node metastases.
Janni W; Rack B; Sommer H; Schmidt M; Strobl B; Rjosk D; Klanner E; Thieleke W; Gerber B; Friese K; Dimpfl T
J Cancer Res Clin Oncol; 2003 Sep; 129(9):503-10. PubMed ID: 12884027
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
